BROOMFIELD, CO / ACCESSWIRE / November 14, 2024 / Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced its participation at the upcoming Virtual Investor Summit Microcap Event on November 21st. The Company will be available for 1-on-1 meetings throughout the day in addition to its formal presentation.Event: Q4 Investor SummitPresentation date and time: November 21, 2024, 3:30pm - 4:00pm ETLocation: https://www.webcaster4.com/Webcast/Page/3075/51667The theme is 40 micro-cap

Fireside Chat Scheduled for 2:00 PM ET on October 15, 2024 BROOMFIELD, Colo., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that Aclarion's CEO, Brent Ness, has been invited to present at the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC, on Tuesday, October 15th, 2024, at 2:00 p.m. E.T. Maxim senior analysts will host a wide range of biotechnology, diagnostic, medical device, and healthcare information technol

Modic Changes (MC) are MRI Findings Associated With Endplate Damage, Neoinnervation, and Chronic Low Back Pain (cLBP) MR Spectroscopy (MRS) Measurement of Intradiscal Propionic Acid (PA) can Clarify MC Etiology and Help Stratify MC Patients to Potentially Inform Better Treatment Decisions for cLBP Patients Results Presented at the 50th International Society for the Study of the Lumbar Spine (ISSLS) Annual Meeting 2024 BROOMFIELD, CO, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the loc

NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an exclusive Q&A with Brent Ness, CEO and Director of Aclarion, Inc. (NASDAQ:ACON). As a disruptive healthcare technology company focused on chronic low back pain, Aclarion is at the forefront of developing noninvasive tools to help physicians identify the source of pain in spinal discs, potentially revolutionizing the standard of care for this widespread and debilitating condition. Aclarion's Nociscan platform, powered by augmented intelligence algorithms and biomarkers, represents a breakthrough in chronic pain treatment. With new commercial agreements, UK payer coverage for Nociscan and over $50 million invested i

Successful milestones achieved and upcoming include peer-reviewed publications, commercial agreements, and payer coverage decisions Progressing with proven path toward standard of care addressing chronic low back pain, the largest expenditure in US healthcare costing Americans an estimated $134 Billion annually More than $50 Million has been invested in the promising Aclarion AI platform that aids physicians in identification of painful discs Technology protected by 23 issued US patents, 17 issued international patents, and 12 pending patent applications Three of four largest private insurance payers in the UK now covering Nociscan Partnership with ten prominent KOL surgeons signed on t

Initial LIFEHAB Enrolled Patients Receive Nociscan Exams to Help Evaluate How Biomarkers in the Discs of the Lumbar Spine Correspond With Treatment Response LIFEHAB is a Randomized Controlled Trial in Norway Comparing Lumbar Interbody Fusion Surgery With Multidisciplinary Rehabilitation LIFEHAB Joins the NIH and Rome in Selecting Nociscan as a Technology to Help Determine Which Discs to Treat and the Technology's Role in Selecting Optimal Treatment Options BROOMFIELD, CO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms t

Company's industry-first technology addresses chronic low back painAclarion secured its first commercial agreement with Michigan's Sheridan Community HospitalPRISM Emerging Medical Devices Index features companies at forefront of innovation and market disruption in medtech NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of market insights and company news, is excited to announce that Aclarion, Inc. (NASDAQ:ACON) has been added to the PRISM Emerging Medical Devices Index, which highlights companies at the forefront of innovation and market disruption in the medtech sector. Aclarion's innovative AI-driven diagnostic solutions for chronic low back pain posit

Justin Kubeck, M.D. of Ocean Pain and Spine in Toms River, NJ Will Lead a Statewide Network of Providers That Use Nociscan to Better Serve This Important Segment of Low Back Pain Population Average Settlement in New Jersey for Personal Injury Claims Involving the Neck and Back is $918,967 Work-related Accidents Which Cause Neck and Back Injuries Have a National Average Settlement of $148,750 BROOMFIELD, CO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chron

CLUE is a Multi-center Trial to Identify how Often Nociscan's AI Data Changes the Initial Treatment Plan for Patients With Chronic Low Back Pain Dr. Justin Kubeck Will Initiate CLUE in New Jersey at Ocean Pain and Spine in Toms River BROOMFIELD, CO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today the expansion of the multi-center CLUE Trial to New Jersey. Justin Kubeck, MD, orthopedic spine surgeon and founder of Ocean Pain and Spine in Toms

Surgeons Will Determine Their Surgical Treatment Plan Before Nociscan and Report on How Often the Surgical Plan Changes After Receiving Nociscan Data Multiple Physicians and Sites Will Enroll in CLUE in the Coming Months Adding Practical Real-world Data to Aclarion's Expanding Body of Clinical Evidence BROOMFIELD, CO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today the launch of the multi-center CLUE Trial to quantify how often a surgeon cha

SC 13G/A - Aclarion, Inc. (0001635077) (Subject)

SC 13G - Aclarion, Inc. (0001635077) (Subject)

SC 13G/A - Aclarion, Inc. (0001635077) (Subject)

SC 13G - Aclarion, Inc. (0001635077) (Subject)

SC 13G - Aclarion, Inc. (0001635077) (Subject)

SC 13G/A - Aclarion, Inc. (0001635077) (Subject)

SC 13G - Aclarion, Inc. (0001635077) (Subject)

SC 13G - Aclarion, Inc. (0001635077) (Subject)

10-Q - Aclarion, Inc. (0001635077) (Filer)

EFFECT - Aclarion, Inc. (0001635077) (Filer)

424B3 - Aclarion, Inc. (0001635077) (Filer)

424B3 - Aclarion, Inc. (0001635077) (Filer)

424B3 - Aclarion, Inc. (0001635077) (Filer)

EFFECT - Aclarion, Inc. (0001635077) (Filer)

S-3 - Aclarion, Inc. (0001635077) (Filer)

S-1 - Aclarion, Inc. (0001635077) (Filer)

EFFECT - Aclarion, Inc. (0001635077) (Filer)

D - Aclarion, Inc. (0001635077) (Filer)

CLUE is a Multi-center Trial to Identify how Often Nociscan's AI Data Changes the Initial Treatment Plan for Patients With Chronic Low Back Pain Dr. Justin Kubeck Will Initiate CLUE in New Jersey at Ocean Pain and Spine in Toms River BROOMFIELD, CO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today the expansion of the multi-center CLUE Trial to New Jersey. Justin Kubeck, MD, orthopedic spine surgeon and founder of Ocean Pain and Spine in Toms

Nicholas Theodore, MD, FACS, FAANS, is Director of Neurosurgical Spine Center, Johns Hopkins, and Professor of Neurosurgery, Orthopaedics and Biomedical Engineering CLARITY is a Post-market, Multi-site Trial That Will Further Evaluate the Role of Nociscan in the Diagnosis and Surgical Ttreatment of Chronic Low Back Pain. CLARITY is Targeted to Begin in the Second Half of 2023. BROOMFIELD, CO, May 02, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pa

Broomfield, CO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that George Frey MD, Founder of the Colorado Comprehensive Spine Institute, will advise the company as a key opinion leader (KOL). Dr. Frey is a renowned surgeon and inventor with dozens of US and worldwide patents in medical devices, technologies, and methods. Dr. Frey's experiences as a clinician and entrepreneur will provide valuable direction to Aclarion.

4 - Aclarion, Inc. (0001635077) (Issuer)

4 - Aclarion, Inc. (0001635077) (Issuer)

4 - Aclarion, Inc. (0001635077) (Issuer)

4 - Aclarion, Inc. (0001635077) (Issuer)

4 - Aclarion, Inc. (0001635077) (Issuer)

4/A - Aclarion, Inc. (0001635077) (Issuer)

4 - Aclarion, Inc. (0001635077) (Issuer)

4 - Aclarion, Inc. (0001635077) (Issuer)

4 - Aclarion, Inc. (0001635077) (Issuer)

4 - Aclarion, Inc. (0001635077) (Issuer)

https://register.epo.org/application?number=EP21157092

Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today an additional key milestone with their second payer coverage of Nociscan by Aviva in London, UK in conjunction with The London Clinic, one of the UK's largest and most renowned independent hospitals. Aviva is a leading provider of private medical insurance in the UK and joins private medical insurance provider, AXA, in covering Nociscan for patients suffering from chronic low back pain. "This second payer coverage decision build

Gainers Akso Health Group (NASDAQ:AHG) shares rose 11.4% to $0.79 during Friday's after-market session. The company's market cap stands at $116.0 million. China SXT Pharmaceuticals (NASDAQ:SXTC) shares increased by 10.43% to $1.27. The company's market cap stands at $1.1 million. CareCloud (NASDAQ:CCLD) stock increased by 10.07% to $2.84. The company's market cap stands at $45.7 million. The company's, Q1 earnings came out 3 days ago. Eledon Pharma (NASDAQ:ELDN) shares moved upwards by 9.63% to $3.31. The company's market cap stands at $125.5 million. OneMedNet (NASDAQ:ONMD) shares increased by 7.52% to $0.5. The market value of their outstanding shares is at $11.9 million. Reshape Lif

Shares of Aon plc (NYSE:AON) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results. Aon posted adjusted earnings of $5.66 per share, missing market estimates of $5.91 per share. The company's sales came in at $4.070 billion versus expectations of $4.126 billion, according to data from Benzinga Pro. Aon shares dipped 7.4% to $283.19 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) shares jumped 73.3% to $1.2475 after the company entered an exclusive license agreement with Rapamycin Holdings for the rights to eRapa. Pineapple Energy Inc. (NASDAQ

Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 61.4% to $1.17 during Friday's regular session. The company's market cap stands at $5.1 million. Agenus (NASDAQ:AGEN) shares rose 32.53% to $11.0. The market value of their outstanding shares is at $230.4 million. Sunshine Biopharma (NASDAQ:SBFM) shares increased by 31.18% to $1.06. The company's market cap stands at $1.0 million. Cullinan Therapeutics (NASDAQ:CGEM) stock moved upwards by 30.85% to $25.19. The company's market cap stands at $1.0 billion. ImmunityBio (NASDAQ:IBRX) shares rose 27.2% to $6.5. The market value of their outstanding shares is at $4.4 billion. Zura Bio (NASDAQ:ZURA) shares increased by 25.69% to $4.55.

Shares of Alphabet Inc. (NASDAQ:GOOGL) (NASDAQ:GOOG) rose sharply in today's pre-market trading the company posted upbeat results for its first quarter. Google parent Alphabet said its first-quarter revenue increased 15% year-over-year to $80.539 billion, beating the consensus estimate of $78.594 billion. The company reported quarterly earnings of $1.89 per share, beating analyst estimates of $1.51 per share, according to data from Benzinga Pro. Alphabet's board authorized an additional share repurchase program of up to $70 billion and also announced its first-ever quarterly dividend. Alphabet shares jumped 11.9% to $174.58 in pre-market trading. Here are some other stocks moving